SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* KAZIMI A J (Last) (First) (Middle) 2525 WEST END AVE. SUITE 950 (Street) NASHVILLE TN 37203 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/10/2009	3. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [ CPIX ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) Chairman and CEO	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,407,563	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	12/18/2001	12/18/2011	Common Stock	6,930	1.63	D
Options	01/15/2005	01/15/2010	Common Stock	10,600	6.6	D
Options	12/31/2005	01/15/2010	Common Stock	10,600	6.6	D
Options	12/31/2006	01/15/2010	Common Stock	10,600	6.6	D
Options	12/31/2006	06/30/2011	Common Stock	5,000	9.9	D
Options	12/31/2007	01/15/2010	Common Stock	10,600	6.6	D
Options	12/31/2007	06/30/2011	Common Stock	5,000	9.9	D
Options	12/31/2008	01/15/2010	Common Stock	10,600	6.6	D
Options	12/31/2008	06/30/2011	Common Stock	5,000	9.9	D
Options	12/31/2008	07/31/2013	Common Stock	7,500	14.3	D
Options	12/31/2009	06/30/2011	Common Stock	5,000	9.9	D
Options	12/31/2009	07/31/2013	Common Stock	7,500	14.3	D
Options	12/31/2009	02/16/2014	Common Stock	7,500	14.3	D
Options	12/31/2010	07/31/2013	Common Stock	7,500	14.3	D
Options	12/31/2010	02/16/2014	Common Stock	7,500	14.3	D
Options	12/31/2011	07/31/2013	Common Stock	7,500	14.3	D
Options	12/31/2011	02/16/2014	Common Stock	7,500	14.3	D
Options	12/31/2012	02/16/2014	Common Stock	7,500	14.3	D

Explanation of Responses:

Remarks:

	A.J. Kazimi by: /s/ Jean W. Marstiller, as Attorney-in-fact	08/10/2009
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.